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L iver disease impairs the absorption, plasma pro-tein binding, and metabolism of numerous 
drugs. l.2 Orthotopic liver transplantation is an ac-
cepted therapeutic option for patients with terminal 
liver failure. 3 The liver is the primary site of plasma 
protein synthesis. Since a major determinant of the 
extent of drug binding to plasma proteins is the con-
centration of the drug-binding proteins, our objec-
tive was to measure the concentrations of two pri-
mary drug-binding proteins, albumin and alpha-1-
acid glycoproteins (AAG), in stable liver transplant 
patients. 
.PA TIENTS AND METHODS 
Fresh heparinized blood (10 ml) was obtained after 
an overnight fast from 16 stable liver transplant pa-
tients (total serum bilirubin;:;; 2.2 mg/dL and serum 
glutamic oxaloacetic transaminase [SGOT] of less 
than 40 IU /L), 12 normal healthy adult volunteers, 
and 7 patients with end-stage liver disease who were 
being considered for liver transplantation. Blood 
samples were obtained from transplant patients 21 
to 146 days after liver transplantation. Plasma was 
separated immediately and ana~yzed for albumin 
and AAG concentrations. Albumin was measured 
by bromocresol green dye binding method4 and 
AAG was measured by a radial immunodiffusion 
method with a commercially available kit (IeL Inter-
national). 
RESULTS 
The minimum detectable concentration of albumin 
and the coefficient of variation of the method used 
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are 1 g/ dL and 3.1%, respectively. The minimum 
detectable concentration of AAG and the coefficient 
of variation of the method used are 20 mg/ dL and 
5.9%, respectively. A summary of the results ob-
tained is presented in the Table. The mean (±SDl 
concentration of albumin in the normal subjects was 
4.5 ± 0.3 g/ dL. This was significantly higher than 
the albumin concentrations in transplant patients 
(3.4 ± 0.7 g/ dL) and in patients with liver disease 
(3.4 ± 0.8 g/ dL). The mean AAG concentration in 
normal subjects was 67 mg/dL. Patients with liver 
disease had a significantly (P < .05) lower AAG con-
centration whereas transplant recipients had a sig-
nificantly (P < .05) higher AAG concentration com-
pared with the normal subjects. Although most of 
the liver transplant recipients had a twofold higher 
AAG concentration, one patient had almost a three-
fold higher AAG concentration than normal sub-
jects. 
DISCUSSION 
Albumin is primarily responsible for the binding of 
acidic drugs whereas basic drugs appear to bind 
preferentially to AAG. The low concentration of al-
bumin and AAG in patients with liver disease indi-
cates the inability of the liver to synthesize these 
drug-binding proteins. Impaired binding of acidic 
and basic drugs is well documented in patients with 
liver disease. 2,5 The albumin concentrations in the 
transplant patients were low despite stable biochem-
icalliver tests. Because albumin is primarily respon-
sible for binding of acidic drugs, liver transplant pa-
tients would not be able to bind acidic drugs as effi-
ciently as the normal subjects. However, the AAG 
concentrations were elevated in all the transplant 
patients studied. AAG is an acute-phase reactant 
and is primarily synthesized in the liver. AAG con-
centrations are known to increase in plasma after 
surgery, 6 myocardial infarction/ renal transplanta-
tion,a malignancy,9 trauma,lO and inflammatory ar-
thritis. l1 Increased binding of certain basic drugs, 
such as propranoloPl and lidocaine,' has been ob-
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-TABLE 
Drug-Binding Proteins in Transplant Patients 
Subjects 
Normal subjects (N = 12) 
Patients with liver disease (N = 7) 
liver transplant patients (N = 16) 
SGOT (lUlL) 
<25 
42-814 
6-38 
• Significantly different from normal subjects (P < .05). 
served in patients with high AAG concentrations. 
Therefore, one would also anticipate increased bind-
ing of basic drugs in liver transplant patients. 
All the liver transplant patients received cyclo-
sporine and prednisone. In addition, some of the pa-
tients received azathioprine, hydralazine, hydro-
chlorothiazide, sulfasalazine, furosemide, or ny-
statin. These drugs are not known to have specific 
effects on albumin or AAG concentrations. 
Although the binding of certain basic drugs may 
be higher in liver transplant patients, binding of 
other basic drugs may not be different from the bind-
ing process in normal subjects because of a compen-
satory reduction in albumin binding. In conclusion, 
our study has documented the presence of elevated 
AAG concentrations in stable liver transplant pa-
tients. The time course of normalization of these 
plasma proteins and the hinding of different basic 
drugs should be examined in liver transplant pa-
tients. 
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Total Bilirubin (mg/dL) 
<1.0 
2.0-54.6 
0.5-2.2 
Albumin (g/dL) 
4.5 ± 0.3 
3.4 ± 0.8* 
3.4 ± 0.7* 
AAG ~ alpha·I·acid glycoprotein. 
AAG (mg/dL) 
67 ± 20 
46 ± 22" 
121 ± 28* 
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